Search bioRxiv⌕ Search

Biology subjects

Chahrour, C.

Publications and source records attributed to Chahrour, C..

3 recordsLinked to original sources

FACT safeguards promoter topology by maintaining nucleosomes and restricting chromatin factor spreading

Facilitates chromatin transcription (FACT) is a histone chaperone that displaces and re-assembles histones during transcription. Recent studies have reported a minor role for FACT in chromatin architecture. We have recently shown that active gene promoters form nanoscale domains and proposed they are created by the biophysical properties of nucleosome-free regions. Here we use base-pair resolution Micro Capture-C ultra to show that, following FACT degradation, nanoscale domains are lost and subnucleosomal chromatin interactions are rearranged at active promoters. Nucleosome-free regions at these promoters expand and chromatin-binding factors invade the newly accessible chromatin, indicating FACT maintains the integrity of active promoters by opposing DNA-binding factor spreading into gene bodies. Finally, we show increased interactions between promoters across topologically associating domains, suggesting large-scale structural changes upon FACT loss. Thus, we demonstrate FACT plays a major role in chromatin organisation and provide in vivo evidence that nucleosomes drive both local and long-range chromatin architecture.

molecular biology↗

Menin maintains enhancer-promoter interactions in a leukemia-specific manner

Inhibition of the protein-protein interaction between Mixed Lineage Leukemia (MLL) and Menin is a promising therapy for both high-risk MLL-rearranged and NPM1-mutant (NPM1c) acute leukemias, yet the mechanistic basis of this dependency in distinct contexts remains unclear. By comparing the transcriptional responses of MLL::AF4 and NPM1c leukemia models to Menin inhibition, we find broad, acute transcriptional dysregulation in MLL::AF4 cells, but minor transcriptional consequences in NPM1c cells, despite similarities in Menin promoter occupancy. Using high-resolution Micro Capture-C, we discover that Menin drives enhancer activity and maintains enhancer-promoter contacts in MLL::AF4 cells but not in NPM1c cells. Crucially, Menin is also essential for patient-specific enhancer function in primary MLL-rearranged leukemia samples. Proteomic analysis further demonstrates that Menin associates with distinct transcriptional and elongation complexes in MLL::AF4 compared to NPM1c cells, supporting a context-dependent mechanism of action. Together, these findings establish that Menin is not a uniform transcriptional cofactor, but a context-dependent regulator of enhancer connectivity, and identifies enhancer-promoter architecture as a selective vulnerability in MLL-rearranged leukemia.

cancer biology↗

Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression between patients

Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogeneity and varied responses to therapy. However, the mechanisms underpinning this heterogeneity remain under-explored. Here, we find that novel enhancer usage is a common feature in acute lymphoblastic leukemia (ALL). In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. Using single cell multiome analysis and extensive chromatin profiling, we reveal that much transcriptional heterogeneity in KMT2A::AFF1 ALL is driven by novel enhancer usage. Using high resolution Micro-Capture-C in primary patient samples, we also identify patient-specific enhancer activity at key oncogenes such as MEIS1 and RUNX2, driving high levels of expression of both oncogenes in a patient-specific manner. Overall, our data show that enhancer heterogeneity is highly prevalent in KMT2A::AFF1 ALL and may also be a mechanism that drives transcriptional heterogeneity in cancer more generally. Key PointsO_LILeukemia patients with the same driver mutations often display gene expression differences C_LIO_LIUsing chromatin profiling and high resolution 3C methods we show that enhancer heterogeneity drives gene expression differences C_LI

cancer biology↗